Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis

2016467 citationsJournal Articlebronze Open Access

Authors

Jason Gotlib · Ludwig-Maximilians-Universität München

Hanneke C. Kluin‐Nelemans · University Medical Center Groningen

Tracy I. George · University Hospital Heidelberg

Cem Akin · University Hospital Heidelberg

Karl Sotlar · University of Lübeck

Olivier Hermine · University Medical Center Groningen

Farrukh T. Awan

Abstract

In this open-label study, midostaurin showed efficacy in patients with advanced systemic mastocytosis, including the highly fatal variant mast-cell leukemia. (Funded by Novartis Pharmaceuticals and others; ClinicalTrials.gov number, NCT00782067.).

Topics & Keywords

Mast cells and histamine Urticaria and Related Conditions Asthma and respiratory diseases

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 374, Issue 26, pp. 2530-2541

DOI: 10.1056/nejmoa1513098

Field-Weighted Citation Impact: 26.80